Regencell Bioscience (RGC) has had the highest return between 2025 and 2026 by a mid-cap US stock, returning 5,636.7%.

ASSET	YEARS	% RETURN
Regencell Bioscience (RGC)	2025-2026	5,636.72%
AXT (AXTI)	2025-2026	2,245.95%
Abivax SA American Depositary Shares (ABVX)	2025-2026	1,115.61%
Sellas Life Sciences (SLS)	2025-2026	968.52%
Kodiak Sciences (KOD)	2025-2026	781.59%
GRAIL, LLC (GRAL)	2025-2026	643.83%
Tango Therapeutics (TNGX)	2025-2026	643.31%
Amylyx Pharmaceuticals (AMLX)	2025-2026	617.68%
Aura Minerals Inc Common Shares (AUGO)	2025-2026	610.19%
ViaSat (VSAT)	2025-2026	598.52%
Almonty Industries Inc Common Shares (ALM)	2025-2026	514.93%
Okeanis Eco Tankers (ECO)	2025-2026	459.22%
Erasca (ERAS)	2025-2026	455.6%
Precigen (PGEN)	2025-2026	415.83%
Definium Therapeutics (DFTX)	2025-2026	400.28%
Celcuity LLC (CELC)	2025-2026	393.57%
10X Genomics (TXG)	2025-2026	393.45%
Par Pacific (PARR)	2025-2026	363.64%
Astronics (ATRO)	2025-2026	346.93%
Relay Therapeutics (RLAY)	2025-2026	338.07%
Delek US Energy (DK)	2025-2026	326.88%
Adaptive Biotechnologies (ADPT)	2025-2026	318.88%
Veradermics (MANE)	2025-2026	308.18%
Oruka Therapeutics (ORKA)	2025-2026	305.21%
SSR Mining (SSRM)	2025-2026	303.51%

Mid-cap stocks are treated as having a market cap between $2B and $10B.